Julie Tucker

Dr. Julie Tucker

University of York, York, UK
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2002 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
TDThomas G. Davies
Thomas G. Davies
JBJohanne Bentley
Johanne Bentley
CAChristine E. Arris
Christine E. Arris
FBF. Thomas Boyle
F. Thomas Boyle
NCNicola Curtin
Nicola Curtin
HWHayley J. Whitfield
Hayley J. Whitfield

7 February 2020 in Science
Verified
Journal Article
Closed access
PDF file
SWStephan Wilmes
Stephan Wilmes
MHMaximillian Hafer
Maximillian Hafer
JVJoni Vuorio
Joni Vuorio
JTJulie Tucker
Julie Tucker
HWHauke Winkelmann
Hauke Winkelmann
JPJacob Piehler
Jacob Piehler
Activated by interaction: Cytokines trigger immune responses when they bind to their cognate receptors. Class I cytokine receptors rely on the associated Janus kinase 2 (JAK2) to initiate signal transduction. There has been debate over whether activation involves ligand-induced dimerization of these receptors or ligand-induced conformational change of preformed dimers. Wilmes et al. imaged cytokine receptors in the plasma membranes of live human cells by single-molecule fluorescence microscopy and observed ligand-induced dimerization. They found that the JAK2 pseudokinase domains contribute to dimerization and that hyperactive JAK2 mutants promote dimerization, consistent with the model that dimerization triggers activation. Science , this issue p. 643

1 August 1996 in Biochemical Journal
Verified
Journal Article
Closed access
JTJulie Tucker
Julie Tucker
RGReinhard Grisshammer
Reinhard Grisshammer
A truncated rat neurotensin receptor (NTR), expressed in Escherichia coli with the maltose-binding protein fused to its N-terminus and the 13 amino acid Bio tag fused to its C-terminus, was purified to apparent homogeneity in two steps by use of the monomeric avidin system followed by a novel neurotensin column. This purification protocol was developed by engineering a variety of affinity tags on to the C-terminus of NTR. Surprisingly, expression levels varied considerably depending on the C-terminal tag used. Functional expression of NTR was highest (800 receptors/cell) when thioredoxin was placed between the receptor C-terminus and the tag, indicating a stabilizing effect of the thioredoxin moiety. Several affinity chromatography methods were tested for purification. NTR with the in vivo-biotinylated Bio tag was purified with the highest efficiency compared with NTR with the Strep tag or a hexa-histidine tail. Co-expression of biotin ligase improved considerably the in vivo biotinylation of the Bio tag and, therefore, the overall purification yield. Proteolysis of the NTR fusion protein was prevented by removing a protease-sensitive site discovered at the N-terminus of NTR. The ligand binding properties of the purified receptor were similar to those of the membrane-bound protein and the native receptor. The scale-up of this purification scheme, to provide sufficient protein for biophysical studies, is in progress.

26 March 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RWRichard A. Ward
Richard A. Ward
CBClaire Brassington
Claire Brassington
Alexander Louis BreezeAlexander Louis Breeze
Alexander Louis Breeze
ACAlessandro Caputo
Alessandro Caputo
SCSusan Critchlow
Susan Critchlow
KHKevin Hudson
Kevin Hudson

27 April 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SBStefan Berg
Stefan Berg
MBMargareta Bergh
Margareta Bergh
SHSven Hellberg
Sven Hellberg
KHKatharina Högdin
Katharina Högdin
YLYvonne Lo-Alfredsson
Yvonne Lo-Alfredsson
RBRatan Bhat
Ratan Bhat

12 October 2016 in ACS Chemical Biology
Verified
Journal Article
Open access
DJDominic I. James
Dominic I. James
KSKate M. Smith
Kate M. Smith
AJAllan Jordan
Allan Jordan
EFEmma E. Fairweather
Emma E. Fairweather
LGLouise A. Griffiths
Louise A. Griffiths
DODonald J. Ogilvie
Donald J. Ogilvie
The enzyme poly(ADP-ribose) glycohydrolase (PARG) performs a critical role in the repair of DNA single strand breaks (SSBs). However, a detailed understanding of its mechanism of action has been hampered by a lack of credible, cell-active chemical probes. Herein, we demonstrate inhibition of PARG with a small molecule, leading to poly(ADP-ribose) (PAR) chain persistence in intact cells. Moreover, we describe two advanced, and chemically distinct, cell-active tool compounds with convincing on-target pharmacology and selectivity. Using one of these tool compounds, we demonstrate pharmacology consistent with PARG inhibition. Further, while the roles of PARG and poly(ADP-ribose) polymerase (PARP) are closely intertwined, we demonstrate that the pharmacology of a PARG inhibitor differs from that observed with the more thoroughly studied PARP inhibitor olaparib. We believe that these tools will facilitate a wider understanding of this important component of DNA repair and may enable the development of novel therapeutic agents exploiting the critical dependence of tumors on the DNA damage response (DDR).